Navigation Links
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Date:6/11/2009

In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate or severe Alzheimer's disease. Further development of dimebon in patients with Huntington disease is also planned. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing, and a Phase 3 trial is expected to begin this year. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the timing and potential results of clinical trials, and the anticipated timing of regulatory filings, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial reso
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Pricing of Public Offering
2. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
3. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
4. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
5. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
8. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
10. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
11. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The FBI recently approved the Promega Power...ating in or generating DNA records for the Nationa...ison, WI USA (PRWEB) -- The FBI recently approved ...by laboratories participating in, or generating DN...). NDIS currently contains more than seven million...
(Date:11/24/2009)...v.24,2009/PRNewswire-FirstCall/--ArenaPharmaceutic...anyisscheduledtopresentatthePiperJaffray21stAnnual...ternTime(8:30a.m.PacificTime)attheNewYorkPalaceHot...fExecutiveOfficer,isscheduledtoprovideanoverviewof...veryprograms. ,, Aliveaudiowebcastofthepresenta...
(Date:11/24/2009)... Chemical Abstracts Service (CAS), the globa...na,s patent office is now the world,s leading prod.... China trailed Japan,s patent office, the World I...United States Patent and Trademark Office (USPTO) ...05, WIPO in 2006, and exceeded Japan for the first...
(Date:11/23/2009)... promises ultra-fast communication, computation an...ion. But trying to use quantum states as carriers ...Now two physicists have shown, mathematically, how...munication, while keeping the information intact. ...ysical Review Letters and highlighted with a View...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
....C., Feb. 25 Attagene Inc., a,biotechnology compa...duction analysis, announced today that one of the ...hip technology, the FACTORIAL(TM). In,advance onli...gei Romanov,with colleagues describes a novel and ...porting on the activity of a large panel of transc...
...b. 25 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA... Phase 3 clinical trial with AZ-004 (Staccato(R) l...e being developed for the treatment of,acute agita...order. Alexza,believes the novel, non-invasive nat...lting from inhaled loxapine administration via the...
...st to Assess Genetic Risk of Thrombosis Improves, ...with Batch Processing, SUNNYVALE, Calif., and LEX...epheid (Nasdaq: CPHD ) and Instrumentation Labora... today announced the release of the Xpert (TM),Hem...roduct under the,European Directive on In Vitro Di...
Other Biology Technology:Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 2Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 2Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 3Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 4Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 5
(Date:11/24/2009)...ion of a remarkable class of ring-shaped protein m...awrence Berkeley National Laboratory (Berkeley Lab... beamline at the Advanced Light Source (ALS). Thes...sion and replication, and are vital to the surviva...gents, such as the human papillomavirus, which has...
(Date:11/24/2009)...YORK (November 24, 2009) -- The Wildlife Conservat...ng that the last remaining population of Siberian ...e rising tide of poaching and habitat loss. , ...sian officials of what needs to be done to protect... , The report was released by the S...
(Date:11/24/2009)...sh food is a matter of debate. A high-profile stud...0 percent of their carbon from trees and leaves, e...ial and aquatic ecosystems. , But new research f... likely to be true. Algae provide a much richer di...esearch published this week in the Proceedings of...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 1European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 2Pioneer of Digital Place Based Media Joins World 26apos 3Bs Leading Blood Pressure and Health Kiosk Manufacturer 51199 1Pioneer of Digital Place Based Media Joins World 26apos 3Bs Leading Blood Pressure and Health Kiosk Manufacturer 51199 2Life Spine 28R 29 Announces FDA Clearance of FS3 28TM 29 Minimally Invasive Spinal System 51196 1
...l repairs or replicates its DNA, the resulting sin...mplex. In eukaryotes or organisms whose cells have...mplex called replication protein A (RPA). Research...ave now unearthed a novel RPA-like complex that sp...NA "tail" end of yeast chromosomes. , Their findin...
...he University of California, Santa Cruz, have dete...nzyme, or "ribozyme," that carries out a fundament...eir results provide insight into what may have bee...lions of years ago on the evolutionary path toward...wn today, the synthesis of DNA and RNA molecules i...
...ack baby" hysteria of the 1980s was greatly exagge...le but disabling cognitive impairments -- attentio...oblems. , A recent study by investigators at the ...velopment may help explain the long-term behaviora...al exposure to cocaine. In a recent issue of the J...
Other Biology News:DNA ends: Common tool, different job 2RNA enzyme structure offers a glimpse into the origins of life 2Prenatal cocaine's lasting cellular effects 2Prenatal cocaine's lasting cellular effects 3
Chicken Anti-Human Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
Anti-p38 MAP Kinase gamma Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-Arg Vasopressin Polyclonal Antibody, Unconjugated from ImmunoStar, Inc.
Goat Anti-Human JIK Polyclonal Antibody, Unconjugated from Abcam
Biology Products: